Enzyme inhibitor combined with chemotherapy delays glioblastoma growth
(University of Alabama at Birmingham) In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 22, 2018 Category: Biology Source Type: news
Glioblastoma in the Elderly: Initial Management Glioblastoma in the Elderly: Initial Management
More elderly patients are being diagnosed with glioblastoma. Are temozolomide and radiotherapy good treatment options for this population?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
DelMar Pharma wins fast track status for glioblastoma drug
DelMar Pharmaceuticals (NSDQ:DMPI) said today that the FDA granted its lead product candidate, VAL-083, fast track status for approval as a therapy for recurrent glioblastoma.
The designation applies to a Phase II trial with the University of Texas MD Anderson Cancer Center and a Phase III trial in patients whose disease has progressed after treatment with temozolomide and bevacizumab.
Get the full story at our sister site, Drug Delivery Business News.
The post DelMar Pharma wins fast track status for glioblastoma drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 29, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Oncology Pharmaceuticals Regulatory/Compliance Wall Street Beat DelMar Pharmaceuticals Source Type: news
Study: Novocure ’ s Optune, drug combo adds months to the lives of GBM patients
Novocure (NSDQ:NVCR) touted today the final analysis of a pivotal Phase III trial that evaluated Optune combined with temozolomide in newly-diagnosed glioblastoma patients.
The analysis, published today in the Journal of the American Medical Association (JAMA), showed that Novocure’s Optune-temozolomide combo extended overall survival and progression-free survival by 37% compared to temozolomide alone.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news
Novocure nabs reimbursement for Optune in Japan
Novocure (NSDQ:NVCR) shares were up this morning after the Japanese Ministry of Health, Labour and Welfare agreed to reimburse for Optune as a treatment for newly-diagnosed glioblastoma.
The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. As a treatment for newly-diagnosed glioblastoma, Novocure combines its device with the anti-cancer drug temozolomide.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure nabs reimbursement for Optune in Japan appeared first on Mass...
Source: Mass Device - December 1, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat NovoCure Source Type: news
Onalespib could be an effective treatment for glioblastoma, preclinical studies show
This study showed that the targeted drug onalespib reduced the expression of cell-survival proteins such as AKT and endothelial growth factor receptor in glioma cell lines and glioma stem cells from patient tumors. This, in turn, reduced the survival, proliferation, invasion and migration of the cells. In animal models of glioblastoma the agent crossed the blood-brain barrier and showed effectiveness as a single agent and greater effectiveness in combination with temozolomide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 2, 2017 Category: International Medicine & Public Health Source Type: news
Temodar (Temozolomide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 25, 2017 Category: Drugs & Pharmacology Source Type: news
ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients
Novocure (NSDQ:NVCR) touted data today from the Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-diagnosed glioblastoma.
The analyses were presented at the American Society for Radiation Oncology’s 2017 annual meeting in San Diego.
Get the full story at our sister site, Drug Delivery Business News.
The post ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news
Zika virus may be useful in treating brain tumours
Conclusion
This is an interesting piece of research that shows how knowledge in one field of medicine can sometimes be applied to another field with surprising results.
But it's important to be realistic about the stage of research. This is very much a "proof of concept" study, and tests on cells, tissues and mice don't necessarily translate into a safe and effective treatment for humans.
The study has several limitations, but the fact the treatment so far hasn't been tested on humans is the most important. For one thing, Zika virus doesn't naturally infect mice, so researchers had to use a specially engineered v...
Source: NHS News Feed - September 6, 2017 Category: Consumer Health News Tags: Cancer Source Type: news
Novocure brings Optune tech to drug trial for glioblastoma
Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma.
The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure brings Optune tech to drug trial for glioblastoma appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 24, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Pharmaceuticals Wall Street Beat Celgene NovoCure Source Type: news
Peptide Vaccine Shows Clinical Benefit in Glioblastoma
A personalized peptide vaccination shows clinical benefit for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Brain Tumors News Source Type: news
Novocure touts quality of life data for Optune, chemo combo
Novocure (NSDQ:NVCR) touted health-related quality of life analyses from a pivotal Phase III trial combining its Optune device with standard temozolomide chemotherapy for patients with newly diagnosed glioblastoma.
The data showed that adding Optune to temozolomide did not negatively impact health-related quality of life, except for itchy skin which the company attributed to skin irritation beneath Optune’s transducer arrays. The combination therapy improved deterioration-free survival of several predefined health-related quality of life scales compared to chemo alone, Novocure reported.
Get the full story at our sis...
Source: Mass Device - May 8, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news
NovoCure launches 2 pediatric trials of TTFields
NovoCure (NSDQ:NVCR) said today it is launching 2 pilot trials exploring the use of tumor treating fields to treat pediatric patients with high grade gliomas.
The St. Helier, N.J.-based company produces the Optune, a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death.
The 1st trial is being sponsored by the Pediatric Brain Tumor Consortium in collaboration with the National Cancer Institute and will study the feasibility of using TTFields on children with recurrent or...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology NovoCure Source Type: news
NovoCure shares rise on Q1 EPS beat
Shares in NovoCure (NSDQ:NVCR) rose today after the medical device maker beat losses per share expectations on Wall Street with its 1st quarter earnings results.
The St. Helier, Jersey-based company posted losses of $18 million, or 21¢ per share, on sales of $34.9 million for the 3 months ended March 31, seeing bottom-line losses shrink 49.1% while sales grew a massive 167.2% compared with the same period in 2016.
Losses per share were ahead of the 24¢ consensus on The Street, while sales fell just short of expectations of $37 million.
“Our growth continued in the 1st quarter 2017. It was the ninth consecutive qua...
Source: Mass Device - April 27, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
This piece of research has led to a Practice Changing Update on DynaMed Plus. It concludes that in elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 20, 2017 Category: Consumer Health News Source Type: news
